



PASPCR

Newsletter

Volume 9 Number 2

June, 2001

Introduction . . .

The **PASPCR Newsletter** is published quarterly and is intended to serve as a means of communication for the members of our Society. As such, we invite our membership to actively contribute to it. If you attend a scientific meeting and heard results which you think will be of interest to the membership of the **PASPCR**, please write a few paragraphs summarizing what was presented and share it with us. Any information on up-coming meetings of interest will also be included. We also want to note any change of affiliation or address that you may have had to help us keep our membership list up-to-date. This is **your Newsletter**, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to Bill Oetting, preferably by Email, to bill@lenti.med.umn.edu.

The **PASPCR Web** page is the major, up-to-date source of current information for the PASPCR membership. The URL address to our home page is <http://www.cbc.umn.edu/paspcr>. The PASPCR Web page contains information about the PASPCR including the goals, ByLaws and Rules of the Society, future meetings, past issues of the **PASPCR Newsletter** as well as links to other related sites including the InterPig DataBase, the International Federation of Pigment Cell Societies (IFPCS) and the regional Pigment Cell Societies from Europe and Japan. In addition, an updated PASPCR membership directory is available on the PASPCR Web page; please notify us if you wish any or all of your information to be modified or deleted on that site. The PASPCR home page also includes positions available and positions wanted. Postings for **Positions Available** are open to all individuals so long as the position is related to pigment cell research. Postings for **Positions Wanted** will be open only to members of the PASPCR or its sister societies (JSPCR and ESPCR). Please provide an expiration data for any submitted postings. If there is additional information that you wish to have added to this web page, please let us know. Send any comments and/or suggestions to the PASPCR WebMaster, Bill Oetting at bill@lenti.med.umn.edu.

Note: The **IFPCS** webpage can be found at www.cbc.umn.edu/ifpcs.

IN THIS ISSUE

| | |
|--|-----|
| Introduction..... | p 1 |
| PASPCR Contact Information..... | p 2 |
| Calendar of Events..... | p 2 |
| Welcome New Council Members..... | p 3 |
| Welcome New Members..... | p 3 |
| Corporate Sponsors..... | p 3 |
| From the Editor - Pigment Cell Research..... | p 4 |
| Extra 17 th IPCC Supplements..... | p.4 |
| And Now, for the Rest of the Story..... | p.4 |
| J. Brumbaugh and the C Locus Chicken | |
| Positions Wanted / Available..... | p 6 |
| Bibliography..... | p 9 |

**PanAmerican Society for
Pigment Cell Research**

c/o **Dr. James J. Nordlund**
Department of Dermatology
University of Cincinnati
231 Bethesda Avenue
Cincinnati, OH 45267-0592
FAX: (513) 558-0198

Officers

Richard A. King
President

Zalfa Abdel-Malek
President-Elect

James J. Nordlund
Secretary/Treasurer

Council Members

Mary K. Cullen

Meenhard Herlyn

Helene Z. Hill

Thomas J. Hornyak

Randy Morrison

Glynis Scott

Miri Seiberg

Vijay Setaluri

Giselle Thibaudeau

IFPCS Representative

Sally Frost-Mason
past-President PASPCR

The **PASPCR Newsletter** is published quarterly; for further information or to submit articles, contact:

Publications Committee:

William S. Oetting, PhD

University of Minnesota
Department of Medicine - Genetics
MMC 485
420 Delaware St. S.E.
Minneapolis, MN 55455
Phone: (612) 624-1139
Email: bill@lenti.med.umn.edu

Vijayasradhi Setaluri, PhD

Wake Forest University School of Medicine
Department of Medicine
Winston-Salem, NC 27157
Phone: (336) 716-3273
Email: setaluri@bgsu.edu

Giselle Thibaudeau, PhD

Mississippi State University
Department of Biological Sciences
Harned Hall
Mississippi State, MS 39762
Phone: (662) 325-7572
Email: Giselle@ra.msstate.edu

Calendar of Events :

Jun 14 - 17, 2001 Xth Annual Meeting of the PanAmerican Society for Pigment Cell Research, to be held in Minneapolis, MN

Contact: Dr. Richard A. King, Department of Medicine, Box 485 Mayo, 420 Delaware St. S.E., Minneapolis, MN 55455;
Phone: (612) 624-0144
Fax: (612) 624-6645
Email: king@mail.ahc.umn.edu.

Sept 27 - 29, 2001 10th Annual Meeting of the European Society for Pigment Cell Research, to be held in Rome, Italy

Contact: Meeting Secretariat, Triumph P.R. S.r.l. Via Proba Petronia 3 00136 ROME - ITALY
Phone ++39.06.399631
Fax ++39.06.39735195
e-mail: espocr2001@triumphpr.it

Dec 1-2, 2001 15th Japanese Society for Pigment Cell Research Meeting (JSPCR) Sendai, Japan,

Contact: Prof. S. Shibahara
E-Mail : shibahar@mail.cc.tohoku.ac.jp

2002 The XVIIIth International Pigment Cell Conference, to be held in The Hague, Holland.

Contact: Dr. Stan Pavel, President ESPCR, University Hospital Leiden, Dept of Dermatology, PO Box 9600, NL - 2300 RC LEIDEN
Phone: 31-(71) 526 1952
Fax: 31-(71) 524 8106;
E-mail: SPavel@algemeen.azl.nl

Sept 3-7, 2003 XIth Annual Meeting of the PanAmerican Society for Pigment Cell Research, to be held in Wood's Hole, MA.

Congratulations to the New Members of the PASPCR Council

Thomas J. Hornyak
Glynis Scott
Miri Seiberg

We wish to thank out-going council members, **Jean L. Bolognia**, **Estela E. Medrano**, and **William J. Pavan**, for their contribution to our society during the last 3 years.

Welcome to New Members

by James J Nordlund

We welcome the following new member to the PASPCR . . .

David A. Brown
Cloris D. Faraco
Marjan Huizing
Ana Luisa Kadekaro
Bonnie L. Richmond
Myung K. Shin

If anyone is interested in joining our Society or wishes to sponsor a member, application forms can be obtained from Dr. James J. Nordlund at the PASPCR Secretary/Treasurer's office.

Corporate Sponsors

by James J Nordlund

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

GOLD Corporate Patrons

Procter and Gamble Co
Shiseido Co, Ltd

SILVER Corporate Patrons

Avon Products, Inc
Galderma Laboratories, Inc
Stiefel Laboratories
Combe, Inc.

From the Editor - *Pigment Cell Research*

Vince Hearing, Editor

Announcement - Anyone interested in obtaining a limited number of back issues of the journal *Pigment Cell Research*, please take note. The former Editors of the journal, Profs. Joseph Bagnara and Jiro Matsumoto, have forwarded all their extra copies of past issues of *Pigment Cell Research* to the current Editorial Office. Anyone who is missing a back issue or two of the journal from their collection can contact the office to request those. Not all back issues are available and they will be provided when available on a first-come, first-served basis. Contact the Editorial Office by Email (editor@pigment.org) and state the issue(s) needed; be sure to provide your full shipping address.

Notice from the Organizers of the 17th IPCC in Nagoya

IPCC-Nagoya Organizers are purchasing a limited number of extra copies of the IPCC Supplement to sell to those who are interested. These issues will cost 5,000 yen (about \$50), and if you would like to reserve and order a copy, please contact Dr. Kazumasa Wakamatsu at kwaka@fujita-hu.ac.jp, and he will send you the information you need.

And now for the rest of the story.

In this issue, we look at the scientific journey Dr. John Brumbaugh, from his 4-H projects on chicken crosses and his discovery of the Punnett square, to gene transfer and mutational analysis of the C-locus in the chicken.

If you wish to know how a particular line of investigation got started, or know of a story that would be interesting to readers of the PASPCR Newsletter, please email me at bill@lenti.med.umn.edu, and I will try to get **the rest of the story**.

Poultry, Pigment, and Plasmids

I never dreamed when I was 6 years old that the color of chicken feathers would form the basis for my entire professional life. It was then I stayed overnight on the broiler farm of some close friends of my parents. Three years later I stayed there the whole summer. My experience developed into a 4-H broiler project. The birds were males of a cross between Barred Plymouth Rock hens and New Hampshire (red) roosters. The birds could be sexed at hatching by noting the light spot on the males' heads.

It wasn't until much later in college that I clearly grasped the Punnett square and became fascinated by genetics. R. C. Punnett, by the way, was a poultry geneticist who published a book in 1923 entitled "Heredity in Poultry" (1) which is dedicated to his mentor" William Bateson whose experiments with poultry offered the first demonstration of Mendelian heredity in the animal kingdom." There was plenty of feather pigment genetics around by the time I received my B.S. in 1958.

When I began graduate school at Iowa State University in the Genetics Department, my advisor was Dr. Willard Hollander. He had 4 ongoing projects: *Drosophila*, mice, pigeons, and chickens. It was an obvious decision. We began the painstaking genetic dissection of the E

locus and some of the buff breeds. Interestingly, the chair of the Zoology Department at ISU at that time was Dr. Howard Hamilton, the author of the chick embryo classic "Lillie's Development of the Chick". Needless to say, he became a member of my Ph. D. committee and helpful mentor. It was early on, that development and genetics came together for me and mechanistic questions arose on several genetic fronts, "Why this and why that??" It was while at ISU that I was introduced to the exciting field of tissue and cell culture.

The Zoology Department at the University of Nebraska became our home in the Fall of 1964. It was not well received to have chickens other than in the Poultry Science Department which was 2 miles away. Rats, mice, opossum, gerbils, guinea pigs, snakes, frogs etc. were OK but not chickens. Reason prevailed and several specific pigment gene stocks were developed with the help of my ever patient graduate students throughout my time at Nebraska.

In the spring of 1966, an important seminar speaker was Dr. Keith Porter, the electron microscope expert, who was then at Harvard. He invited me to spend the summer there learning how to use the TEM. I think he was intrigued by the ultrastructure of premelanosomes. Some preliminary micrographs were obtained that summer which led to some serious investigations for at least a decade. TEM coupled with ultrastructural autoradiography and DOPA incubation led to some interesting ideas about the effects of several mutations. Some mysteries were revealed but some "Whys?" definitely remained!

Some time in the early 1970's our department was given a grant to bring in special speakers for several days. I invited Dr. Howard Holtzer of the U. of Pennsylvania who was looking at substances that controlled differentiation. As a result, I was invited to his laboratory to learn how to grow cell cultures of chick melanocytes. My early interests in tissue and cell culture now became a reality! As a result of this collaboration we were able to do heterokaryon studies, similar in principle to those used with Neurospora, using cell fusion techniques. Not only did we find complementation or noncomplementation using various mutations, but saw some "reprogramming" of differentiation using red blood cells (they are nucleated in birds) and fibroblasts. We were getting closer to defining some of the mutations, but some "Why's" remained.

In the 1980's I began to collaborate with Dr. Gary Smith in our department. He was a first rate cell culturist and virologist. He introduced us to the use of conditioned medium from the BRL-3A cell line to increase our yield. We coupled this with the mitotic stimulatory effects of the phorbol ester, TPA. We now could grow large enough quantities of pure melanocytes to do protein studies.

At that same time Dr. Hiroaki Yamamoto joined our lab group and showed us how to do enzyme isolations and electrophoresis. This enabled us to do some neat experiments. We isolated undifferentiated cells under the influence of TPA and using 2-D electrophoresis mapped the proteins present. Similar cultures were released from the TPA and subsequently differentiated. Many new proteins appeared and the putative tyrosinase isozymes were identified. Several mutations were compared. The tentative conclusion was that the autosomal albino mutation was a structural mutation. We were getting closer!

In the mid 1980's I met Dr. Steve Hughes of the NCI in Frederick, MD. As a retrovirologist he had developed a plasmid that allowed cDNA's to be spliced into the Avian Leukosis Virus. He agreed to collaborate as did Dr. Yamamoto (now back in Japan) and the late Dr. Takeuchi. Dr. Hughes supplied the plasmid and Drs. Yamamoto and Takeuchi the cDNA for mouse tyrosinase. We spliced in the mouse tyrosinase cDNA and subsequently infected cultured albino chick melanocytes and "cured" the albinism!

Several selective promoters, other than the native, constitutive ALV promoter, were tested by Dr. Toyoko Akiyama who was visiting our lab in the early 1990's from Keio Univ. of Japan. Finally, the viruses were placed into early chick embryos with some success. This was done with the additional collaboration of Dr. Don Salter then of Michigan State U. If the mouse tyrosinase gene "cured" chick albinism with an appropriate promoter, then the "odds" were that it was the structural gene, but absolute proof was still lacking!

Dr. Akiyama supplied the final proof last year by showing that the autosomal albino mutation was the result of a 6 base pair deletion. The road has ended for this mutation. The journey begun so long ago has been driven to the DNA level. There are other mutations and other questions, so I wish "good hunting" to those who follow behind me. It will be an exciting and marvelous journey as mine has been!

N.B. In this essay, I have only mentioned by name mentors and collaborators. During my tenure, I had a host of graduate students and technicians. They were immeasurably important! To them I say, "You are not and will not be forgotten!"

REFERENCES

1. Punnett, R. C., 1923, "Heredity in Poultry", Macmillan, London.
2. Hamilton, H. L., 1952, "Lillie's Development of the Chick", Henry Holt & Co., New York.

Positions - Wanted and Available :

Research Associate/Post Doctoral Fellow Position Available

Position available for either an entry level postdoctoral fellow or a more senior research associate to study the molecular and cellular biology of the melanocyte in general and the pathophysiology of vitiligo in specific. The research project will focus globally on the role of survival factors and apoptotic regulators on the viability of melanocytes in the skin and in culture. In addition, the project will focus on the genetic and cellular susceptibility of melanocytes from patients with vitiligo to under apoptosis in response to various stimuli. Postdoctoral fellow candidate should have experience with routine molecular and cellular techniques including cell culturing, site directed mutagenesis, and protein biochemistry. Research Associate candidate should have similar experiences utilizing the melanocyte system. Candidate will become part of an interactive research group focusing of various aspects of pigmentation in the Department of Dermatology and on skin physiology in the Skin Sciences Institute within the University of Cincinnati College of Medicine. Send curriculum vitae and list of three references to:

Raymond E. Boissy, Ph.D.
Professor of Dermatology and
Cell Biology, Neurobiology, & Anatomy
Department of Dermatology
University of Cincinnati College of Medicine
231 Albert Sabin Way, ML-0592
Cincinnati, OH, 45267-0592

TEL: 513-558-6242
FAX: 513-558-0198
E-mail: boissyre@email.uc.edu

Postdoctoral Research Position

A postdoctoral position is available immediately to study the transcriptional co-repressor and co-activator activities of the oncogenic protein Ski in human melanomas (PNAS (USA) 97:5924-5929, 2000). Seeking individuals with experience in EMSA, *in vitro* transcription-translation, site-directed mutagenesis and yeast two-hybrid screening. Interested individuals should send inquiries and applications (including CV, a brief description of past experience and future research interests, and the name of three references) to:

Estela E. Medrano, Ph.D.
Huffington Center on Aging
Baylor College of Medicine
One Baylor Plaza N-803.01
Houston, TX 77030

Baylor College of Medicine is an Equal Opportunity Employer

Principal Scientist- Clinical Research - Skin Science Research

Unilever employs over 200 scientists at our New Jersey Laboratory who are dedicated to innovative and scientifically rigorous skin research programs. Our world sales exceed \$40 billion so our programs have solid financial funding allowing for an innovative and challenging research culture. We currently have a full time opening that provides a unique opportunity to apply your basic science skills to human studies that impact the condition of skin for hundreds of millions people worldwide. We are seeking an expert in pigment biology or photobiology who can advance our knowledge and link laboratory research to clinically defined improvements of consumer skin problems. As a member of our skin research team, you will have an opportunity to work with other scientific experts in many fields including cell biology, biochemistry, measurement science and physical chemistry. You will also be encouraged to establish and maintain close ties to research in academic and government research communities.

We offer a competitive salary, benefits including tuition assistance and relocation, and a dynamic environment filled with learning and discovery beyond conventional scientific boundaries. Applicants must be authorized to work in the USA. For consideration please forward your CV to: Human Resources, Dept. CR-SID, Unilever Research US, 45 River Road, Edgewater, NJ 07020 or E-Mail: job.mca@unilever.com . Please place only the letters "CR-SID" as the subject of your e-mail. Unilever is an Equal Opportunity Employer m/f/d/v.

Postdoctoral Fellows - Cancer and Developmental Biology - Two NIH-funded positions are available for fellows interested in studying the Hedgehog signaling pathway in development and disease using skin as a model system. One project centers on defining the function of the Hedgehog pathway during skin appendage morphogenesis (Dev. Biol. 205: 1-9, 1999); a second project focuses on understanding how deregulated activation of this pathway gives rise to basal cell carcinomas (Nature Genet. 24: 216-7, 2000). Applicants should have a solid background in molecular and cell biology, with experience in transgenic animal models desirable but not required. Interested individuals should send a CV, letter of interest, and names of three references to: Dr. Andrzej Dlugosz, University of Michigan, Department of Dermatology and Comprehensive Cancer Center, 3310 CCGC, Box 0932, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0932 Email: dlugosza@umich.edu. The University of Michigan is an Equal Opportunity Employer.

Postdoctoral Research Associate - Position available to study the biology of human inherited disorders of pigmentation using gene transfer technology. The successful applicant will have a Ph.D. and/or M.D. with experience in cell biology and molecular biology. Experience in gene transfer/genome manipulation is preferred. Please send curriculum vitae along with the names of three references to Dr. Richard King, Division of Genetics, Department of Medicine, Box 485 Mayo, 420 Delaware St. S.E., University of Minnesota, Minneapolis, MN 55455. Equal Opportunity Employer.

Postdoctoral Position - Ph.D. in molecular biology, biophysics, genetics or biochemistry. Position available to conduct research on molecular mechanisms of cellular response to oxidative stress in human melanocytes and melanoma cells and its regulation for preventive and therapeutic indications. Contact Dr. Frank L. Meyskens Jr., Director, University of California-Irvine, Chao Family Clinical Cancer Research Center, 101 The City Drive, Orange, CA 92668, USA. Fax (714) 456-5039 Email flmeyske@uci.edu

Bibliography :

The Bibliography published in this issue covers the period March, 2001 through May, 2001. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. By its very nature, assignment of a reference to a particular category is arbitrary and we urge you to read through all categories to make sure you don't miss any pertinent to your field. We have attempted to highlight any publications which include a member of the PASPCR with a star (*sorry if we missed you but let us know and you'll get a free marked repeat in the next issue*).

MELANINS, MELANOGENS & MELANOGENESIS

- ❖ Bartels S, Ito S, Trune DR, Nuttall AL: Noise-induced hearing loss: the effect of melanin in the stria vascularis. *HEAR RES* 154:116-123 (2001).
- Borges CR, Roberts JC, Wilkins DG, Rollins DE: Relationship of melanin degradation products to actual melanin content: Application to human hair. *ANAL BIOCHEM* 290:116-125 (2001).
- Dehn DL, Claffey DJ, Duncan MW, Ruth JA: Nicotine and cotinine adducts of a melanin intermediate demonstrated by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *CHEM RES TOXICOL* 14:275-279 (2001).
- Feng B, Wang X, Hauser M, Kaufmann S, Jentsch S, Haase G, Becker JM, Szaniszló PJ: Molecular cloning and characterization of WdPKS1, a gene involved in dihydroxynaphthalene melanin biosynthesis and virulence in *Wangiella* (*Exophiala*) dermatitidis. *INFEC IMMUNITY* 69:1781-1794 (2001).
- Hoffmann K, Stücker M, Altmeyer P, Teuchner K, Leupold D: Selective femtosecond pulse-excitation of melanin fluorescence in tissue. *J INVEST DERMATOL* 116:629-630 (2001).
- Hyun HJ, Sohn JH, Ha DW, Ahn YH, Koh JY, Yoon YH: Depletion of intracellular zinc and copper with TPEN results in apoptosis of cultured human retinal pigment epithelial cells. *INVEST OPHTHALMOL VISUAL SCI* 42:460-465 (2001).
- Ichinose K, Ebizuka Y, Sankawa U: Mechanistic studies on the biomimetic reduction of tetrahydroxynaphthalene, a key intermediate in melanin biosynthesis. *CHEM PHARM BULL TOKYO* 49:192-196 (2001).
- Kim DS, Kim SY, Moon SJ, Chung JH, Kim KH, Cho KH, Park KC: Ceramide inhibits cell proliferation through Akt/PKB inactivation and decreases melanin synthesis in Mel-Ab cells. *PIGM CELL RES* 14:110-115 (2001).
- Kobayashi N, Katsumi S, Imoto K, Nakagawa A, Miyagawa S, Furumura M, Mori T: Quantitation and visualization of ultraviolet-induced DNA damage using specific antibodies: Application to pigment cell biology. *PIGM CELL RES* 14:94-102 (2001).
- Korac B, Buzadzic B: Glutathione S-transferase activity in the rat skin in relation to melanin. *CHEM BIOL INTER* 133:304-307 (2001).
- Méjanelle L, López JF, Gunde-Cimerman N, Grimalt JO: Ergosterol biosynthesis in novel melanized fungi from hypersaline environments. *J LIPID RES* 42:352-358 (2001).
- ❖ Parichy DM: Homology and evolutionary novelty in the deployment of extracellular matrix molecules during pigment pattern formation in the salamanders *Taricha torosa* and *T-rivularis* (Salamandridae). *J EXP ZOOL* 291:13-24 (2001).
- Rättö M, Chatani M, Ritschkoff AC, Viikari L: Screening of micro-organisms for decolorization of melanins produced by bluestain fungi. *APPL MICROBIOL BIOTECHNOL* 55:210-213 (2001).
- Shet TM, Balasubramaniam M, Rege J: Melanin pigment in aspirates from epidermal cysts. *ACTA CYTOL* 45:284-285 (2001).
- Smith JR, O'Rourke LM, Becker MD, Cao M, Williams KA, Planck SR, Rosenbaum JT: Anti-rat ICAM-1 antibody does not influence the course of experimental melanin-induced uveitis. *CURR EYE RES* 21:906-912 (2000).
- Zecca L, Gallorini M, Schünemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D: Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. *J NEUROCHEM* 76:1766-1773 (2001).

MELANOCYTES & KERATINOCYTES

- Assad SA, Bernstein EF, Brod B, James WD: Extensive pigmentation secondary to minocycline treatment of rheumatoid arthritis. *J RHEUMATOL* 28:679-682 (2001).
- Autier P, Boniol M, Severi G, Giles G, Cattaruzza MS, Luther H, Renard F, Grivegnée AR, Pedoux R, Doré JF: The body site distribution of melanocytic naevi in 6-7 year old European children. *MELANOMA RES* 11:123-131 (2001).
- ❖ Bahadoran P, Aberdam E, Mantoux F, Buscà R, Bille K, Yalman N, deSaint-Basile G, Casaroli-Marano R, Ortonne JP, Ballotti R: Rab27a: A key to melanosome transport in human melanocytes. *J CELL BIOL* 152:843-849 (2001).
- Bauer BS, Few JW, Chavez CD, Galiano RD: The role of tissue expansion in the management of large congenital pigmented nevi of the forehead in the pediatric patient. *PLAST RECONSTR SURG* 107:668-675 (2001).
- Bauer JW, Schaeppi H, Kaserer C, Hantich B, Hintner H: Large melanocytic nevi in hereditary epidermolysis bullosa. *J AMER ACAD DERMATOL* 44:577-584 (2001).
- ❖ Berking C, Herlyn M: Human skin reconstruct models: A new application for studies of melanocyte and melanoma biology. *HISTOL HISTOPATHOL* 16:669-674 (2001).

- ❖ Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M: Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. *AMER J PATHOL* 158:943-953 (2001).
- ❖ Bertolotto C, Busca R, Ballotti R, Ortonne JP: Cyclic AMP is a key messenger in the regulation of skin pigmentation. *M S MED SCI* 17:177-185 (2001).
- Binder M, Kittler H: Changes even in benign melanocytic nevi - Reply. *ARCH DERMATOL* 137:228-229 (2001).
- Binder M, Kittler H: Enlarging common melanocytic nevi and the diagnosis of malignant melanoma - Reply. *ARCH DERMATOL* 137:227-228 (2001).
- Botchkareva NV, Khlgtatian M, Longley BJ, Botchkarev VA, Gilchrest BA: SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. *FASEB J* 15:645-658 (2001).
- Böhm M, Schiller M, Nashan D, Stadler R, Luger TA, Metze D: Diffuse melanosis arising from metastatic melanoma: Pathogenetic function of elevated melanocyte peptide growth factors. *J AMER ACAD DERMATOL* 44:747-754 (2001).
- Braun RP, Saurat JH: Changes even in benign melanocytic nevi. *ARCH DERMATOL* 137:228 (2001).
- Brodell RT: Enlarging common melanocytic nevi and the diagnosis of malignant melanoma. *ARCH DERMATOL* 137:227 (2001).
- Burke KE, Clive J, Combs GF, Commisso J, Keen CL, Nakamura RM: Effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. *NUTR CANCER* 38:87-97 (2000).
- Chen YF, Yang PY, Hung CM, Hu DH: Transplantation of autologous cultured melanocytes for treatment of large segmental vitiligo. *J AMER ACAD DERMATOL* 44:543-545 (2001).
- Clarkson KS, Sturdgess IC, Molyneux AJ: The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). *J CLIN PATHOL* 54:196-200 (2001).
- Crespel E, Plantin P, Schoenlaub P, Blayo M, Queinnec C, Broussine L: Hyperpigmentation of the distal phalanx in healthy Caucasian neonates. *EUROPEAN J DERMATOLOGY* 11:120-121 (2001).
- ❖ Erf GF, Bersi TK, Wang XL, Sreekumar GP, Smyth JR: Herpesvirus connection in the expression of autoimmune vitiligo in Smyth line chickens. *PIGM CELL RES* 14:40-46 (2001).
- Ewanowich C, Brynes RK, Medeiros LJ, McCourty A, Lai R: Cyclin D1 expression in dysplastic nevi - An immunohistochemical study. *ARCH PATHOL LAB MED* 125:208-210 (2001).
- Faraco CD, Vaz SAS, Pástor MVD, Erickson CA: Hyperpigmentation in the Silkie fowl correlates with abnormal migration of fate-restricted melanoblasts and loss of environmental barrier molecules. *DEVELOP DYNAM* 220:212-225 (2001).
- Foster RD, Williams ML, Barkovich AJ, Hoffman WY, Mathes SJ, Frieden IJ: Giant congenital melanocytic nevi: The significance of neurocutaneous melanosis in neurologically asymptomatic children. *PLAST RECONSTR SURG* 107:933-941 (2001).
- Georgieva J, Sinha P, Schadendorf D: Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. *J CLIN PATHOL* 54:229-235 (2001).
- Granter SR, McKee PH, Calonje E, Mihm MC, Busam M: Melanoma associated with blue nevus and melanoma mimicking cellular blue nevus - A clinicopathologic study of 10 cases on the spectrum of so-called 'malignant blue nevus'. *AMER J SURG PATHOL* 25:316-323 (2001).
- Granter SR, Weilbaecher KN, Quigley C, Fletcher CDM, Fisher DE: Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: Further evidence for melanocytic differentiation. *MODERN PATHOL* 14:6-9 (2001).
- Green D, Friedman KJ: Treatment of minocycline-induced cutaneous pigmentation with the Q-switched Alexandrite laser and a review of the literature. *J AMER ACAD DERMATOL* 44:342-347 (2001).
- Haas N, Schadendorf D, Hermes B, Henz BM: Hypomelanosis due to block of melanosomal maturation in amiodarone-induced hyperpigmentation. *ARCH DERMATOL* 137:513-514 (2001).
- Hachiya A, Kobayashi A, Ohuchi A, Takema Y, Imokawa G: The paracrine role of stem cell factor/c-kit signaling in the activation of human melanocytes in ultraviolet-B-induced pigmentation. *J INVEST DERMATOL* 116:578-586 (2001).
- Hamoan KE, Rinkes IHMB, Morgan JR: Hepatocyte growth factor and melanoma: gene transfer studies in human melanocytes. *MELANOMA RES* 11:89-97 (2001).
- ❖ Hornyak TJ, Hayes DJ, Chiu LY, Ziff EB: Transcription factors in melanocyte development: distinct roles for Pax-3 and Mitf. *MECH DEVELOP* 101:47-59 (2001).
- Hume AN, Collinson LM, Rapak A, Gomes AQ, Hopkins CR, Seabra MC: Rab27a regulates the peripheral distribution of melanosomes in melanocytes. *J CELL BIOL* 152:795-808 (2001).
- Irvine AD, Rugg EL, Lane EB, Hoare S, Peret C, Hughes AE, Heagerty AH: Molecular confirmation of the unique phenotype of epidermolysis bullosa simplex with mottled pigmentation. *BRIT J DERMATOL* 144:40-45 (2001).
- Ivanova K, Das PK, VandenWijngaard RMJG, Lenz W, Klockenbring T, Malcharzyk V, Drummer C, Gerzer R: Differential expression of functional guanylyl cyclases in melanocytes: Absence of nitric-oxide-sensitive isoform in metastatic cells. *J INVEST DERMATOL* 116:409-416 (2001).
- Jang KA, Choi JH, Sung KJ, Moon KC, Koh JK: Idiopathic eruptive macular pigmentation: Report of 10 cases. *J AMER ACAD DERMATOL* 44:351-353 (2001).
- Jimbow K, Chen H, Park JS, Thomas PD: Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. *BRIT J DERMATOL* 144:55-65 (2001).
- Katz J: Use of minocycline and soft tissue pigmentation: Close association. *ARCH DERMATOL* 137:372 (2001).
- Khumalo NP, Joss DV, Huson SM, Burge S: Pigmentary anomalies in ataxia-telangiectasia: a clue to diagnosis and an example of twin spotting. *BRIT J DERMATOL* 144:369-371 (2001).
- Lai CH, Lockhart S, Mallory SB: Typical halo nevi in childhood: Is a biopsy necessary? *J PEDIAT* 138:283-284 (2001).
- Lei JY, Middleton LP, Guo XD, Duray PH, McWilliams G, Linehan WM, Merino MJ: Pigmented renal clear cell carcinoma with melanocytic differentiation. *HUM PATHOL* 32:233-236 (2001).
- Masuda M, Usami SI, Yamazaki K, Takumi Y, Shinkawa H, Kurashima K, Kunihiro T, Kanzaki J: Connexin 26 distribution in gap junctions between melanocytes in the human vestibular dark cell area. *ANAT REC* 262:137-146 (2001).
- Na RH, Stender IM, Henriksen M, Wulf HC: Autofluorescence of human skin is age-related after correction for skin pigmentation and redness. *J INVEST DERMATOL* 116:536-540 (2001).

- Phillips J, Gawkrödger DJ, Caddy CM, Hedley S, Dawson RA, Smith-Thomas L, Freedlander E, MacNeil S: Keratinocytes suppress TRP-1 expression and reduce cell number of co-cultured melanocytes - Implications for crafting of patients with vitiligo. *PIGM CELL RES* 14:116-125 (2001).
- Price ER, Fisher DE: Sensorineural deafness and pigmentation genes: Melanocytes and the Mitf transcriptional network. *NEURON* 30:15-18 (2001).
- ❖ Quevedo ME, Slominski A, Pinto W, Wei E, Wortsman J: Pleiotropic effects of corticotropin releasing hormone on normal human skin keratinocytes. *IN VITRO CELL DEV BIOL ANIMAL* 37:50-54 (2001).
 - Raposo G, Tenza D, Murphy DM, Berson JF, Marks MS: Distinct protein sorting and localization to premelanosomes, melanosomes, and lysosomes in pigmented melanocytic cells. *J CELL BIOL* 152:809-823 (2001).
 - Roh KY, Kim D, Ha SJ, Ro YJ, Kim JW, Lee HJ: Pigmentation in Koreans: study of the differences from caucasians in age, gender and seasonal variations. *BRIT J DERMATOL* 144:94-99 (2001).
 - Rubegni P, Cevenini G, Burroni M, Perotti R, Dell'Eua G, Andreassi L: Digital dermoscopy analysis of pigmented skin lesions: An important auxiliary for clinical decision and not for automatic diagnosis. *ARCH DERMATOL* 137:378 (2001).
 - Salti GI, Kichina JV, DasGupta TK, Uddin S, Bratescu L, Pezzuto JM, Mehta RG, Constantinou AI: Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. *MELANOMA RES* 11:99-104 (2001).
 - ❖ Sarangarajan R, Shumaker H, Soleimani M, LePoole C, Boissy RE: Molecular and functional characterization of sodium-hydrogen exchanger in skin as well as cultured keratinocytes and melanocytes. *BBA BIOMEMBRANES* 1511:181-192 (2001).
 - ❖ Schaffer JV, Orlow SJ, Lazova R, Bologna JL: Speckled lentiginous nevus - Within the spectrum of congenital melanocytic nevi. *ARCH DERMATOL* 137:172-178 (2001).
 - Scherschun L, Lee MW, Lim HW: Diltiazem-associated photodistributed hyperpigmentation - A review of 4 cases. *ARCH DERMATOL* 137:179-182 (2001).
 - Schrama D, Andersen MH, Terheyden P, Schroder L, Pedersen LO, Straten PT, Becker JC: Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. *CANCER RES* 61:493-496 (2001).
 - Schubert C, Parwaresch R, Rudolph P: A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus. *VIRCHOWS ARCHIV* 438:166-172 (2001).
 - ❖ Schwahn DJ, Xu WD, Herrin AB, Bales ES, Medrano EE: Tyrosine levels regulate the melanogenic response to α -melanocyte-stimulating hormone in human melanocytes: Implications for pigmentation and proliferation. *PIGM CELL RES* 14:32-39 (2001).
 - ❖ Scott G, Zhao Q: Rab3a and SNARE proteins: Potential regulators of melanosome movement. *J INVEST DERMATOL* 116:296-304 (2001).
 - Suzuki T, Yasumoto Y, Kumami K, Matsumura K, Kumami M, Mochizuki M, Suzuki H, Kojima H: Primary pineal melanocytic tumor - Case report. *J NEUROSURG* 94:523-527 (2001).
 - Takayama H, Nagashima Y, Hara M, Takagi H, Mori M, Merlino G, Nakazato Y: Immunohistochemical detection of the c-met proto-oncogene product in the congenital melanocytic nevus of an infant with neurocutaneous melanosis. *J AMER ACAD DERMATOL* 44:538-540 (2001).
 - Tobin DJ, Paus R: Graying: gerontobiology of the hair follicle pigmentary unit (vol 36, pg 29, 2001). *EXP GERONTOL* 36:591-592 (2001).
 - ❖ Toyofuku K, Wada I, Spritz RA, Hearing VJ: The molecular basis of oculocutaneous albinism type 1 (OCA1): sorting failure and degradation of mutant tyrosinases results in a lack of pigmentation. *BIOCHEM J* 355:259-269 (2001).
 - Valery C, Vasseur S, Sabatier F, Iovanna JL, Dagorn JC, Grob JJ, Verrando P: Pancreatitis associated protein I (PAP-I) alters adhesion and motility of human melanocytes and melanoma cells. *J INVEST DERMATOL* 116:426-433 (2001).
 - Wehrle-Haller B, Meller M, Weston JA: Analysis of melanocyte precursors in Nf1 mutants reveals that MGF/KIT signaling promotes directed cell migration independent of its function in cell survival. *DEVELOP BIOL* 232:471-483 (2001).
 - Wu XF, Rao K, Bowers MB, Copeland NG, Jenkins NA, Hammer JA: Rab27a enables myosin Va-dependent melanosome capture by recruiting the myosin to the organelle. *J CELL SCI* 114:1091-1100 (2001).
 - Yanase H, Ando H, Horikawa M, Watanabe M, Mori T, Matsuda N: Possible involvement of ERK 1/2 in UVA-induced melanogenesis in cultured normal human epidermal melanocytes. *PIGM CELL RES* 14:103-109 (2001).

MELANOMA & METASTASIS

- Ten years of Melanoma Research: what has changed in the melanoma field? *MELANOMA RES* 11:87 (2001).
- Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S: Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. *INVEST OPHTHALMOL VISUAL SCI* 42:313-317 (2001).
- Ahmed NU, Shioda T, Coser KR, Ichihashi M, Ueda M: Aberrant expression of MSG1 transcriptional activator in human malignant melanoma in vivo. *PIGM CELL RES* 14:140-143 (2001).
- Ahrens T, Assmann V, Fieber C, Termeer CC, Herrlich P, Hofmann M, Simon JC: CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. *J INVEST DERMATOL* 116:93-101 (2001).
- Allen BJ, Rizvi SMA, Tian Z: Preclinical targeted α therapy for subcutaneous melanoma. *MELANOMA RES* 11:175-182 (2001).
- Amin HM, Petruzzelli GJ, Husain AN, Nickoloff BJ: Primary malignant melanoma of the larynx. *ARCH PATHOL LAB MED* 125:271-273 (2001).
- Asai T, Shuto S, Matsuda A, Kakiuchi T, Ohba H, Tsukada H, Oku N: Targeting and anti-tumor efficacy of liposomal 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-b-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma. *CANCER LETT* 162:49-56 (2001).
- Ascierto PA, Caracò C, Ionna F, Pezzullo L, Palmieri G, Melucci MT, Canzanella S: Mobile hospital rooms to fight melanoma. *MELANOMA RES* 11:83-84 (2001).
- Aubin F, Humbery O, Humbert P, Laurent R, Mouglin C: Melanoma and ultraviolet light: from physiology to pathology. *PRESSE MEDICALE* 30:546-551 (2001).

- August C, Baba HA, Heinig J, Nashan D, Höhn P, Holzhausen HJ, Metze D, Böcker W: Endometrial metastasis of a balloon cell melanoma mimicking a xanthomatous endometritis. *PATHOLOGIE* 22:145-150 (2001).
- Auzeloux P, Papon J, Pasqualini R, Madelmont JC: Synthesis and biodistribution of a new oxo-technetium-99m bis(aminothioliol) complex as a potential melanoma tracer. *J MED CHEM* 44:1116-1121 (2001).
- Avril MF, Chompert A, Verne-Fourment L, Terrier-Lacombe MJ, Spatz A, Fizazi K, Bressac-dePaillerets B, Demenais F, Théodore C: Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma. *MELANOMA RES* 11:117-122 (2001).
- Bantel-Schaal U: Integration of adeno-associated virus 2 DNA in human MKr melanoma cells induces a peptide with oncosuppressive properties. *INT J CANCER* 92:537-544 (2001).
- Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L: Dual inactivation of RB and p53 pathways in RAS-induced melanomas. *MOL CELL BIOL* 21:2144-2153 (2001).
- Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T: Phase II evaluation of bryostatatin-1 in metastatic melanoma. *MELANOMA RES* 11:183-188 (2001).
- Berset M, Cerottini JP, Guggisberg D, Romero P, Burri F, Rimoldi D, Panizzon RG: Expression of Melan-A/MART-1 antigen as a prognostic reactor in primary cutaneous melanoma. *INT J CANCER* 95:73-77 (2001).
- Bertalot G, Dell'Orto P, Viale G: Binding of rabbit immunoglobulins to melanoma cells: a pitfall in the immunohistochemical study of malignant melanoma - Authors' reply. *VIRCHOWS ARCHIV* 438:423 (2001).
- Blaheta HJ, Sotlar K, Breuninger H, Bueltmann B, Rassner G, Garbe C, Horny HP: Does intensive histopathological workup by serial sectioning increase the detection of lymph node micrometastasis in patients with primary cutaneous melanoma? *MELANOMA RES* 11:57-63 (2001).
- Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, deHerreros AG, Dunach M, Neckers LM: Geldanamycin abrogates ErbB2 association with proteasome-resistant b-catenin in melanoma cells, increases b-catenin-E-cadherin association, and decreases b-catenin-sensitive transcription. *CANCER RES* 61:1671-1677 (2001).
- Brar SS, Kennedy TP, Whorton AR, Sturrock AB, Huecksteadt TP, Ghio AJ, Hoidal JR: Reactive oxygen species from NAD(P)H: quinone oxidoreductase constitutively activate NF- κ B in malignant melanoma cells. *AMER J PHYSIOL CELL PHYSIOL* 280:C659-C676 (2001).
- Braun-Falco M, Hallek M: Recombinant adeno-associated virus (rAAV) vector-mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response. *ARCH DERMATOL RES* 293:12-17 (2001).
- Brownbridge GG, Gold J, Edward M, Mackie RM: Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. *BRIT J DERMATOL* 144:279-287 (2001).
- Busam KJ: Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma. *AMER J CLIN PATHOL* 115:743-746 (2001).
- Casagrande F, Darbon JM: Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. *BIOCHEM PHARMACOL* 61:1205-1215 (2001).
- Chen HB, Chen L, Zhong JK, Chow VW, Wu BQ, Wang ZH, Cheng SB, Chew EC: Expression of laminin in metastatic melanoma cell lines with different metastatic potential. *ANTICANCER RES* 21:505-508 (2001).
- Chen SL, Hong YH, Scherer SJ, Schartl M: Lack of ultraviolet-light inducibility of the medakafish (*Oryzias latipes*) tumor suppressor gene p53. *GENE* 264:197-203 (2001).
- Chim CS, Smith NJT: Primary malignant ocular melanoma: a bone marrow diagnosis. *BRIT J HAEMATOL* 112:2 (2001).
- Christmann M, Pick M, Lage H, Schadendorf D, Kaina B: Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. *INT J CANCER* 92:123-129 (2001).
- Cokgor I, Akabani G, Friedman HS, Friedman AH, Zalutsky MR, Zehngbot LM, Provenzale JM, Guy CD, Wikstrand CJ, Bigner DD: Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2) - A case study. *CANCER* 91:1809-1813 (2001).
- Connelly TJ: Sentinel lymph node mapping and biopsy in the evaluation of primary melanoma. *J AMER ACAD DERMATOL* 44:876-877 (2001).
- Conti EMS, Cercato MC, Gatta G, Ramazzotti V, Roscioni S: Childhood melanoma in Europe since 1978: a population-based survival study. *EUR J CANCER* 37:780-784 (2001).
- Daftari I, Barash D, Lin S, O'Brien J: Use of high-frequency ultrasound imaging to improve delineation of anterior uveal melanoma for proton irradiation. *PHYS MED BIOL* 46:579-590 (2001).
- DeLarco JE, Wuertz BRK, Manivel JC, Furcht LT: Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. *CANCER RES* 61:2857-2861 (2001).
- Demary K, Wong L, Spanjaard RA: Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. *CANCER LETT* 163:103-107 (2001).
- Demirci H, Shields CL, Shields JA, Eagle RC, Honavar SG: Bilateral breast metastases from choroidal melanoma. *AMER J OPHTHALMOL* 131:521-523 (2001).
- DiFronzo LA, Wanek LA, Morton DL: Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. *CANCER* 91:1520-1524 (2001).
- Dimitrakopoulou-Strauss A, Strauss LG, Burger C: Quantitative PET studies in pretreated melanoma patients: A comparison of ⁶-[F-18] fluoro-L-dopa with F-18-FDG and O-15-water using compartment and noncompartment analysis. *J NUCL MED* 42:248-256 (2001).
- Drewa G, Wozniak A, Palgan K, Schachtschabel DO, Grzanka A, Sujkowska R: Influence of quercetin on B16 melanotic melanoma growth in C57BL/6 mice and on activity of some acid hydrolases in melanoma tissue. *NEOPLASMA* 48:12-18 (2001).
- Drzewiecka A, Urbanska K, Matuszak Z, Pineiro M, Arnaut LG, Habdas J, Ratuszna A, Stochel G: Tritolylporphyrin dimer as a new potent hydrophobic sensitizer for photodynamic therapy of melanoma. *ACTA BIOCHIM POL* 48:277-282 (2001).

- Eskelin S, Kivelä T: Uveal melanoma: Implications of tumor doubling time - Author's reply. *OPHTHALMOLOGY* 108:830-831 (2001).
- Esser P, Grisanti S, Bartz-Schmidt KU: TGF- β in uveal melanoma. *MICROSC RES TECHNIQUE* 52:396-400 (2001).
- Fabris P, DallaPalma M, deLalla F: Idiosyncratic acute hepatitis caused by paracetamol in two patients with melanoma treated with high-dose interferon- α . *ANN INTERN MED* 134:345 (2001).
- Farkas DL, Becker D: Applications of spectral imaging: Detection and analysis of human melanoma and its precursors. *PIGM CELL RES* 14:2-8 (2001).
- Fersht N, Spittle MF: Some aspects of radiotherapy for melanoma. *BRIT J DERMATOL* 144:1-2 (2001).
- Fishman D, Irena B, Kellman-Pressman S, Karas M, Segal S: The role of MHC class I glycoproteins in the regulation of induction of cell death in immunocytes by malignant melanoma cells. *PROC NAT ACAD SCI USA* 98:1740-1744 (2001).
- Forslund K, Nordqvist K: The melanoma antigen genes - Any clues to their functions in normal tissues? *EXP CELL RES* 265:185-194 (2001).
- Friedrich U, Houman M, Hansen BH, Kaltoft K: Microdissection and reverse painting in a melanoma cell line: a detailed description of structurally abnormal chromosomes. *CANCER GENET CYTOGENET* 125:5-9 (2001).
- Frost PA, Butterfield LH, Dissette VB, Economou JS, Bonavida B: Immunosenitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. *J IMMUNOL* 166:3564-3573 (2001).
- Fröhlich E, Schlagenhauß B, Möhrle M, Weber E, Klessen C, Rassner G: Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. *CANCER* 91:972-982 (2001).
- Fuhrmann D, Lippold A, Borrosch F, Ellwanger U, Garbe C, Suter L: Should adjuvant radiotherapy be recommended following resection of regional lymph node metastases of malignant melanomas? *BRIT J DERMATOL* 144:66-70 (2001).
- Fuss M, Loredò LN, Blacharski PA, Grove RI, Slater JD: Proton radiation therapy for medium and large choroidal melanoma: Preservation of the eye and its functionality. *INT J RADIAT ONCOL BIOL PHYS* 49:1053-1059 (2001).
- Gaikwad SY, Jagtap AG, Ingle AD, Ra SGA, Gude RP: Antimetastatic efficacy of niosomal pentoxifylline and its combination with activated macrophages in murine B16F10 melanoma model. *CANCER BIOTHER RADIOPHARM* 15:605-615 (2000).
- Gasparollo A, Coral S, Ciullo M, Prisco A, Cattarossi I, Sigalotti L, Altomonte M, Guardiola J, Maio M: Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN- γ . *INT J CANCER* 91:500-507 (2001).
- Giermasz A, Nowis D, Jalili A, Basak G, Marczak M, Makowski M, Czajka A, Mlynarczuk I, Hoser G, Stok T, Lewandowski S, Jakóbisziak M: Antitumor activity of tributyrin in murine melanoma model. *CANCER LETT* 164:143-148 (2001).
- Goggins WB, Finkelstein DM, Tsao H: Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. *CANCER* 91:874-880 (2001).
- Goldman BD, Rich P: Subungual melanoma obscured by nail polish. *J AMER ACAD DERMATOL* 44:875 (2001).
- Grossniklaus HE, Dithmar S, Albert DM: Animal models of uveal melanoma (vol 10, pg 195, 2000). *MELANOMA RES* 11:85 (2001).
- ❖ Gruss C, Herlyn M: Role of cadherins and matrixins in melanoma. *CURR OPIN ONCOL* 13:117-123 (2001).
- Günther K, Fleischer A, Buettner R, Bosserhoff AK: Detection of invasion-related chromosomal changes in highly and weakly invasive melanoma cell clones by a modified comparative genomic hybridization approach. *MELANOMA RES* 11:105-115 (2001).
- Habal N, Giuliano AE, Morton DL: The use of sentinel lymphadenectomy to identify candidates for postoperative adjuvant therapy of melanoma and breast cancer. *SEMIN ONCOL* 28:41-52 (2001).
- Halachmi S, Gilchrist BA: Update on genetic events in the pathogenesis of melanoma. *CURR OPIN ONCOL* 13:129-136 (2001).
- Harada M, Li YF, El Gamil M, Rosenberg SA, Robbins PF: Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells. *CANCER RES* 61:1089-1094 (2001).
- Harlow SP, Krag DN, Ashikaga T, Weaver DL, Meijer SJ, Loggie BW, Tanabe KK, Whitworth P, Kuhn J, Kusminsky R, Carp NZ, Gadd M, Rawlings M, Slingluff CL: Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. *MELANOMA RES* 11:45-55 (2001).
- Hashemi J, Bendahl PO, Sandberg T, Platz A, Linder S, Stierner U, Olsson H, Ingvar C, Hansson J, Borg A: Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families. *GENE CHROMOSOME CANCER* 31:107-116 (2001).
- Hauschild A, Christophers E: Sentinel node biopsy in melanoma. *VIRCHOWS ARCHIV* 438:99-106 (2001).
- Hauschild A, Oratz R, Sebastian G: Intratumoral cisplatin/epinephrine injectable gel for treatment of patients with cutaneous and soft tissue metastases of malignant melanoma: an international Multicenter study (vol 11, pg S223, 2001). *MELANOMA RES* 11:203 (2001).
- Hauschild A, Möller M, Lischner S, Christophers E: Repeatable acute rhabdomyolysis with multiple organ dysfunction because of interferon α and dacarbazine treatment in metastatic melanoma. *BRIT J DERMATOL* 144:215-216 (2001).
- Heinzel S, Rea D, Offringa R, Pawelec G: The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4⁺T lymphocytes to recognize melanoma cells. *CANCER IMMUNOL IMMUNOTHER* 49:671-678 (2001).
- Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G, Moelling K: Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. *J MOLECULAR MED JMM* 78:692-702 (2001).
- Helmke BM, Deichmann M, Otto HF: Anorectal melanomas do not harbour the Kaposi sarcoma-associated human herpesvirus type 8 DNA. *J MED VIROL* 64:47-50 (2001).
- Hemminki K, Lönnstedt I, Vaitinen P: A population-based study of familial cutaneous melanoma. *MELANOMA RES* 11:133-140 (2001).
- Hillner BE, Kirkwood JM, Agarwala SS: Burden of illness associated with metastatic melanoma - An audit of 100 consecutive referral center cases. *CANCER* 91:1814-1821 (2001).
- Hosaka Y, Higuchi T, Tsumagari M, Ishii H: Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. *CANCER LETT* 161:231-240 (2000).

- ❖ Houghton AN, Gold JS, Blachere NE: Immunity against cancer: lessons learned from melanoma. *CURR OPIN IMMUNOL* 13:134-140 (2001).
- Huerta C, Rodríguez LAG: Incidence of ocular melanoma in the general population and in glaucoma patients. *J EPIDEMIOL COMMUNITY HEALTH* 55:338-339 (2001).
- Huncharek M, Caubet JF, McGarry R: Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. *MELANOMA RES* 11:75-81 (2001).
- Ichihashi N, Kitajima Y: Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells. *BRIT J DERMATOL* 144:745-750 (2001).
- Invernizzi R, Pecci A: A case of metastatic malignant melanoma with bone marrow involvement. *HAEMATOLOGICA* 86:447 (2001).
- Ivanov VN, Fodstad O, Ronai Z: Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNF α and suppression of NF- κ B activities. *ONCOGENE* 20:2243-2253 (2001).
- Jemal A, Devesa SS, Hartge P, Tucker MA: Recent trends in cutaneous melanoma incidence among whites in the United States. *J NAT CANCER INST* 93:678-683 (2001).
- Jevtovic-Todorovic V, Guenther TM: Sensitization of human melanoma cells to melphalan cytotoxicity by Adriamycin and carmustine, (vol 117, pg 313, 1991). *J CANCER RES CLIN ONCOL* 127:329 (2001).
- Johnson FE, Virgo KS, Johnson DY, Chan D, Goshima K, Handler BS: Effect of initial tumor stage on patient follow-up after potentially curative surgery for cutaneous melanoma. *INT J ONCOL* 18:973-978 (2001).
- Kamarashev J, Ferrone S, Seifert B, Böni R, Nestle FO, Burg G, Dummer R: TAP1 down-regulation in primary melanoma lesions: An independent marker of poor prognosis. *INT J CANCER* 95:23-28 (2001).
- Kang DC, Jiang HP, Wu QP, Pestka S, Fisher PB: Cloning and characterization of human ubiquitin-processing protease-43 from terminally differentiated human melanoma cells using a rapid subtraction hybridization protocol RaSH. *GENE* 267:233-242 (2001).
- Kanzler MH, Mraz-Gernhard S: Treatment of primary cutaneous melanoma. *JAMA J AM MED ASSN* 285:1819-1821 (2001).
- Kaskel P, Kunzi-Rapp K, Leiter U, Peter RU, Krähn G: Soluble p185/her2 and S100 in yolk sac blood from human melanoma metastases xenotransplanted to chick embryo chorioallantoic membrane. *ANTICANCER RES* 20:5065-5068 (2000).
- Kawakami Y, Wang X, Shofuda T, Sumimoto H, Tupesis JP, Fitzgerald E, Rosenberg SA: Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. *J IMMUNOL* 166:2871-2877 (2001).
- Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL: Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. *J CLIN ONCOL* 19:1176-1182 (2001).
- Kirkwood JM, Ibrahim J, Lawson DH, Aikins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696. *J CLIN ONCOL* 19:1430-1436 (2001).
- Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801. *J CLIN ONCOL* 19:2370-2380 (2001).
- Kirkwood JM: Adjuvant therapy of melanoma: At what cost? In reply. *J CLIN ONCOL* 19:1226-1228 (2001).
- Kraehn GM, Utikal J, Udart M, Greulich KM, Bezold G, Kaskel P, Leiter U, Peter RU: Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. *BRIT J CANCER* 84:72-79 (2001).
- Kretschmer L, Neumann C, Preusser KP, Marsch WC: Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin - An analysis of survival and local recurrence. *ACTA ONCOL* 40:72-78 (2001).
- Kulik J, Nowecki ZI, Rutkowski P, Ruka W, Rochowska M, Skurzak H, Siedlecki JA: Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay. *MELANOMA RES* 11:65-73 (2001).
- Kunz M, Ibrahim S, Koczan D, Thiesen HJ, Köhler HJ, Acker T, Plate KH, Ludwig S, Rapp UR, Bröcker EB, vanMuijen GNP, Flory E, Gross G: Activation of c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. *CELL GROWTH DIFFER* 12:137-145 (2001).
- Kunzi-Rapp K, Kaskel P, Steiner R, Peter RU, Krähn G: Increased blood levels of human S100 in melanoma chick embryo xenografts' circulation. *PIGM CELL RES* 14:9-13 (2001).
- Kuwahara A, Katano M, Nakamura M, Morisaki T, Miyazaki K, Fujimoto K: Expression of melanoma antigen-encoding gene-1 predicts lymph node involvement in early gastric carcinomas. *DIGEST DIS SCI* 46:262-267 (2001).
- Lafuma A, Dreno B, Delaunay M, Emery C, Fagnani F, Hieke K, Bonerandi JJ, Grob JJ: Economic analysis of adjuvant therapy with interferon α -2a in stage II malignant melanoma. *EUR J CANCER* 37:369-375 (2001).
- Lage H, Helmbach H, Grottko C, Dietel M, Schadendorf D: DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. *FEBS LETT* 494:54-59 (2001).
- Lambert WC, Lapidus A, Rao BK: Melanoma diagnosis by computerized analysis of clinical images. *ARCH DERMATOL* 137:377 (2001).
- Langezaal SM, vanRoggen JFG, Cleton-Jansen AM, Baelde JJ, Hogendoorn PCW: Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). *BRIT J CANCER* 84:535-538 (2001).
- Laube F: Co-localization of CD44 and urokinase-type plasminogen activator on the surface of human melanoma cells. *ANTICANCER RES* 20:5045-5048 (2000).
- ❖ Li G, Satyamoorthy K, Herlyn M: N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. *CANCER RES* 61:3819-3825 (2001).
- Mackie RM, Stewart B, Brown SM: Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. *LANCET* 357:525-526 (2001).
- Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC: The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. *MELANOMA RES* 11:11-19 (2001).

- Maria DA, Ribeiro OG, Pizzocaro KF, DeFranco M, Cabrera WK, Starobinas N, Gallois V, Siqueira M, Seman M, Ibañez OM: Resistance to melanoma metastases in mice selected for high acute inflammatory response. *CARCINOGENESIS* 22:337-342 (2001).
- Marrett LD, Nguyen HL, Armstrong BK: Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983-1996. *INT J CANCER* 92:457-462 (2001).
- Mastrangelo G, Rossi CR, Pfahlberg A, Marzia V, Barba A, Baldo M, Fadda E, Milan G, Kölmel KF: Is there a relationship between influenza vaccinations and risk of melanoma? A population-based case-control study. *EUR J EPIDEMIOL* 16:777-782 (2000).
- Mårtensson ED, Hansson LO, Nilsson B, vonSchoultz E, Brahme EM, Ringborg U, Hansson J: Serum S-100B protein as a prognostic marker in malignant cutaneous melanoma. *J CLIN ONCOL* 19:824-831 (2001).
- Måseide K, Lyng H, Rofstad EK: Microvessel oxyhemoglobin saturation does not reflect tissue oxygen tension in human melanoma xenografts. *MICROVASCULAR RES* 61:199-202 (2001).
- Menaker GM, Chiang JK, Tabala B, Moy RL: Rapid HMB-45 staining in Mohs micrographic surgery for melanoma in situ and invasive melanoma. *J AMER ACAD DERMATOL* 44:833-836 (2001).
- Menzies SW: Epiluminescence microscopy diagnostic criteria with follow-up computer-based monitoring of "Less suspicious" lesions may increase sensitivity for the diagnosis of melanoma while maintaining adequate specificity. *ARCH DERMATOL* 137:378-379 (2001).
- Micallef MJ, Darmanin S, Buhagiar JA, Camilleri-Podesta MT, Yamauchi H, Kurimoto M, Inglott AS, Ellul-Micallef R: Interferon γ induction in human melanoma cell/allogeneic leukocyte co-cultures is enhanced by interleukin 18 but drug resistant melanoma cells are poorer inducers of IFN- γ . *INT IMMUNOPHARMACOL* 1:295-305 (2001).
- Mijnhout GS, Hoekstra OS, vanTulder MW, Teule GJJ, Devillé WLJM: Systemic review of the diagnostic accuracy of F-18-fluorodeoxyglucose positron emission tomography in melanoma patients. *CANCER* 91:1530-1542 (2001).
- Miller CG, Krummenacher C, Eisenberg RJ, Cohen GH, Fraser NW: Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1. *MOL THER* 3:160-168 (2001).
- Moshari A, Cheeseman EW, McLean IW: Totally necrotic choroidal and ciliary body melanomas: Associations with prognosis, episcleritis, and scleritis. *AMER J OPHTHALMOL* 131:232-236 (2001).
- Moy CS: Evidence for the role of sunlight exposure in the etiology of choroidal melanoma. *ARCH OPHTHALMOL* 119:430-431 (2001).
- Nagore E, Climent J, Planelles MD, Ledesma E, Rubio-Moscardó F, Fortea JM, Oliver V: Analysis of the CDKN2A and CDK4 genes and HLA-DR and HLA-DQ alleles in two Spanish familial melanoma kindreds. *ACTA DERMATO VENEREOL* 80:440-442 (2000).
- Nakayama T, Taback B, Turner R, Morton DL, Hoon DSB: Molecular clonality of in-transit melanoma metastasis. *AMER J PATHOL* 158:1371-1378 (2001).
- Naseri A, Char DH, Howes E, Paglen P: Amelanotic corneal melanoma after a blast injury. *AMER J OPHTHALMOL* 131:259-260 (2001).
- Nathanson L: Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma - A commentary. *CANCER* 91:881-888 (2001).
- Naus NC, vanDrunen E, deKlein A, Luyten GPM, Paridaens DA, Alers JC, Ksander BR, Beverloo HB, Slater RM: Characterization of complex chromosomal in uveal melanoma by fluorescence in situ hybridization, spectral karyotyping, and comparative genomic hybridization. *GENE CHROMOSOME CANCER* 30:267-273 (2001).
- Nawrath M, Pavlovic J, Moelling K: Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model. *J MOLECULAR MED JMM* 79:133-142 (2001).
- Nguyen CL, McClay EF, Cole DJ, O'Brien PH, Gillanders WE, Metcalf JS, Maize JC, Baron PL: Melanoma thickness and histology predict sentinel lymph node status. *AMER J SURG* 181:8-11 (2001).
- Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri VM, Pyrhönen S: High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma. *MELANOMA RES* 11:157-166 (2001).
- Nischt R, Wallich M, Reibetanz M, Baumann P, Krieg T, Mauch C: BM-40 and MMP-2 expression are not coregulated in human melanoma cell lines. *CANCER LETT* 162:223-230 (2001).
- Noll WW, Belloni DR, Rutter JL, Storm CA, Schned AR, Titus-Ernstoff L, Ernstoff MS, Brinckerhoff CE: Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. *AMER J PATHOL* 158:691-697 (2001).
- O'Brien J: Uveal melanoma: Implications of tumor doubling time - Invited commentary. *OPHTHALMOLOGY* 108:831-832 (2001).
- Olsson H, Andersson H, Bladström A, Borg Å, Ingvar C, Möller T, Westerdahl J: Re: High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families - Response. *J NAT CANCER INST* 93:324-325 (2001).
- Osborne JE, Hutchinson PE: Clinical correlates of Breslow thickness of malignant melanoma. *BRIT J DERMATOL* 144:476-483 (2001).
- Owen SA, Sanders LL, Edwards LJ, Seigler HF, Tyler DS, Grichnik JM: Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV. *CANCER* 91:983-991 (2001).
- Pahernik S, Langer S, Botzlar A, Dellian M, Goetz AE: Tissue distribution and penetration of 5-ALA induced fluorescence in an amelanotic melanoma after topical application. *ANTICANCER RES* 21:59-63 (2001).
- Palermo B, Campanelli R, Mantovani S, Lantelme E, Manganoni AM, Carella G, DaPrada G, dellaCuna GR, Romagne F, Gauthier L, Necker A, Giachino C: Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients. *EUR J IMMUNOL* 31:412-420 (2001).
- Palmieri G, Ascierto PA, Cossu A, Mozzillo N, Motti ML, Satriano SMR, Botti G, Caracò C, Celentano E, Satriano RA, Lissia A, Tanda F, Pirastu M: Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. *J CLIN ONCOL* 19:1437-1443 (2001).

- Parmar J, Marshall ES, Charters GA, Holdaway KM, Shelling AN, Baguley BC: Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. *ONCOL RES* 12:149-155 (2000).
- Paterson ICM, Beer H, Jones DA: Under-registration of melanoma in Wales in 1998: use of the capture-recapture method to estimate the 'true' incidence. *MELANOMA RES* 11:141-145 (2001).
- Pelayo BA, Fu YM, Meadows GG: Decreased tissue plasminogen activator and increased plasminogen activator inhibitors and increased activator protein-1 and specific promoter 1 are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine. *INT J ONCOL* 18:877-883 (2001).
- Perez M, Migliaccio S, Taranta A, Festuccia C, Orrù L, Brama M, Bologna M, Faraggiana T, Baron R, Teti A: Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines. *EUR J CANCER* 37:629-640 (2001).
- Peter I, Mezzacasa A, LeDonne P, Dummer R, Hemmi S: Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. *MELANOMA RES* 11:21-30 (2001).
- Pfahlberg A, Kölmel KF, Gefeller O: Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation-induced melanoma. *BRIT J DERMATOL* 144:471-475 (2001).
- Pizzichetta MA, Argenziano G, Talamini R, Piccolo D, Gatti A, Trevisan G, Sasso G, Veronesi A, Carbone A, Soyer HP: Dermoscopic criteria for melanoma in situ are similar to those for early invasive melanoma. *CANCER* 91:992-997 (2001).
- Plna K, Hemminki K: Re: High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. *J NAT CANCER INST* 93:323-324 (2001).
- Poetsch M, Dittberner T, Woenckhaus C: PTEN/MMAC1 in malignant melanoma and its importance for tumor progression. *CANCER GENET CYTOGENET* 125:21-26 (2001).
- Pollock PM, Welch J, Hayward NK: Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. *CANCER RES* 61:1154-1161 (2001).
- Quesnel A, Zerbib A, Connan F, Guillet JG, Briand JP, Choppin J: Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein. *J PEPT SCI* 7:157-165 (2001).
- Reinhold U, Berkin C, Bosserhoff AK, Deutschmann A, Garbe C, Gläser R, Hein R, Krähn G, Peter RU, Rapp G, Schittek B, Seiter S, Ugurel S, Volkenandt M, Tilgen W: Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzyme-linked immunosorbent assay for the detection of circulating melanoma cells: A multicenter study of the dermatologic cooperative oncology group. *J CLIN ONCOL* 19:1723-1727 (2001).
- Rettenbacher L, Koller J, Kässmann H, Holzmannhofer J, Rettenbacher T, Galvan G: Reproducibility of lymphoscintigraphy in cutaneous melanoma: Can we accurately detect the sentinel lymph node by expanding the tracer injection distance from the tumor site? *J NUCL MED* 42:424-429 (2001).
- Ricci R, Maggiano N, Martini M, Mulé AMA, Pierconti F, Capelli A, Larocca LM: Primary malignant melanoma of the gallbladder in dysplastic naevus syndrome. *VIRCHOWS ARCHIV* 438:159-165 (2001).
- Robson A, Allen P, Hollowood K: S100 expression in cutaneous scars: a potential diagnostic pitfall in the diagnosis of desmoplastic melanoma. *HISTOPATHOLOGY* 38:135-140 (2001).
- Roosendaal GK, deVries JDH, vanPoll D, Jansen L, Koops HS, Nieweg OE, Kroon BBR: Sentinel nodes outside lymph node basins in patients with melanoma. *BRIT J SURG* 88:305-308 (2001).
- Ros-Bullón MR, Sánchez-Pedreño P, Martínez-Liarte H: Serum ceruloplasmin in melanoma patients. *ANTICANCER RES* 21:629-632 (2001).
- Rubegni P, Ferrari A, Cevenini G, Piccolo D, Burrioni M, Perotti R, Peris K, Taddeucci P, Biagioli M, Dell'Eva G, Chimenti S, Andreassi L: Differentiation between pigmented Spitz naevus and melanoma by digital dermoscopy and stepwise logistic discriminant analysis. *MELANOMA RES* 11:37-44 (2001).
- Safa MM, Foon KA: Adjuvant immunotherapy for melanoma, and colorectal cancers. *SEMIN ONCOL* 28:68-92 (2001).
- Salopek TG, Scott JR, Joshua AV, Smylie M, Logus JW, Morin CA, McEwan AJB: Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9): a new potential melanoma imaging agent. *EUR J NUCL MED* 28:408-417 (2001).
- Schmitz C, Brenner W, Henze E, Christophers E, Hauschild A: Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. *ANTICANCER RES* 20:5059-5063 (2000).
- Schmuth M, Spötl L, Zelger BG, Weinlich G, Zelger B: Clear cells in acral melanoma. *EUROPEAN J DERMATOLOGY* 11:21-24 (2001).
- Schofield PE, Beeney LJ, Thompson JF, Butow PN, Tattersall MHN, Dunn SM: Hearing the bad news of a cancer diagnosis: The Australian melanoma patient's perspective. *ANN ONCOL* 12:365-371 (2001).
- Schwab RE, Froidevaux S, Paku S, Tejada M, Szende B, Pap A, Beglinger C, Eberle AN, Kéri G: Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours. *ANTICANCER RES* 21:71-75 (2001).
- Seiter S, Stassar M, Rapp G, Reinhold U, Tilgen W, Zöller M: Upregulation of C4.4 A expression during progression of melanoma. *J INVEST DERMATOL* 116:344-347 (2001).
- Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C: Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. *CANCER RES* 61:1095-1099 (2001).
- Shaaran M, Heller D, Sama J: Periurethral vaginal melanoma: Urine cytologic findings. *ACTA CYTOL* 45:285-286 (2001).
- Shannon JA, Kefford RF, Mann GJ: Responses to ultraviolet-B in cell lines from hereditary melanoma kindreds. *MELANOMA RES* 11:1-9 (2001).
- Siegel DM, McClain SA: Angiotropic malignant melanoma: More common than we think? *J AMER ACAD DERMATOL* 44:870-871 (2001).
- Sileni VC, Nortilli R, Aversa SML, Paccagnella A, Medici M, Corti L, Favaretto AG, Cetto GL, Monfardini S: Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. *MELANOMA RES* 11:189-196 (2001).
- Singh AD: Uveal melanoma: Implications of tumor doubling time. *OPHTHALMOLOGY* 108:829-830 (2001).

- Smyth J, Boneterre ME, Schellens J, Calvert H, Greim G, Wanders J, Hanauske A: Activity of the dolastatin analogue, LU103793, in malignant melanoma. *ANN ONCOL* 12:509-511 (2001).
- Spatz A, Giglia-Mari G, Benhamou S, Sarasin A: Association between DNA repair-deficiency and high level of p53 mutations in melanoma of xeroderma pigmentosum. *CANCER RES* 61:2480-2486 (2001).
- Spitler LE: Adjuvant therapy of melanoma: At what cost? *J CLIN ONCOL* 19:1226 (2001).
- Spring PM, Myers JN, El Naggar AK, Langstein HN: Malignant melanoma arising within a burn scar - Case report and review of the literature. *ANN OTOL RHINOL LARYNGOL* 110:369-376 (2001).
- Stahlecker J, Gauger A, Bosserhoff A, Büttner R, Ring J, Hein R: MIA as a reliable tumor marker in the serum of patients with malignant melanoma. *ANTICANCER RES* 20:5041-5044 (2000).
- Stante M, DeGiorgi V, Cappugi P, Giannotti B, Carli P: Non-invasive analysis of melanoma thickness by means of dermoscopy: a retrospective study. *MELANOMA RES* 11:147-152 (2001).
- Stern RS: The risk of melanoma in association with long-term exposure to PUVA. *J AMER ACAD DERMATOL* 44:755-761 (2001).
- Stoll R, Renner C, Zweckstetter M, Brüggert M, Ambrosius D, Palme S, Engh RA, Golob M, Breibach I, Buettner R, Voelter W, Holak TA, Bosserhoff AK: The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold. *EMBO J* 20:340-349 (2001).
- Sulkowska M, Famulski W, Bakunowicz-Lazarczyk A, Chyczewski L, Sulkowski S: Bcl-2 expression in primary uveal melanoma. *TUMORI* 87:54-57 (2001).
- Taran JM, Heenan PJ: Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. *CANCER* 91:1822-1825 (2001).
- Tartaglia J, Bonnet MC, Berinstein N, Barber B, Klein M, Moingeon P: Therapeutic vaccines against melanoma and colorectal cancer. *VACCINE* 19:2571-2575 (2001).
- Thelmo MC, Sagebiel RW, Treseler PA, Morita ET, Nguyen LH, Kashani-Sabet M, Leong SPL: Evaluation of sentinel lymph node status in spindle cell melanomas. *J AMER ACAD DERMATOL* 44:451-455 (2001).
- Thies A, Moll I, Berger J, Schumacher U: Lectin binding to cutaneous malignant melanoma: HPA is associated with metastasis formation. *BRIT J CANCER* 84:819-823 (2001).
- Thomas R, Padmanabha J, Chambers M, McFadyen S, Walpole E, Nielssen G, Smithers M: Metastatic lesions in the joint associated with acute inflammatory arthritis after dendritic cell immunotherapy for metastatic melanoma. *MELANOMA RES* 11:167-173 (2001).
- Tomescu D, Kavanagh G, Ha T, Campbell H, Melton DW: Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. *CARCINOGENESIS* 22:403-408 (2001).
- Tosaka M, Tamura M, Oriuchi N, Horikoshi M, Joshita T, Sugawara K, Kobayashi S, Kohga H, Yoshida T, Sasaki T: Cerebrospinal fluid immunocytochemical analysis and neuroimaging in the diagnosis of primary leptomeningeal melanoma - Case report. *J NEUROSURG* 94:528-532 (2001).
- Tscharscher F, Prescher G, Horsman DE, White VA, Rieder H, Anastassiou G, Schilling H, Bornfeld N, Bartz-Schmidt KU, Horsthemke B, Lohmann DR, Zeschnigk M: Partial deletions of the long and short arm of chromosome 3 point to two tumor suppressor genes in uveal melanoma. *CANCER RES* 61:3439-3442 (2001).
- Unger JM, Flaherty LE, Liu PY, Albain KS, Sondak VK: Gender and other survival predictors in patients with metastatic melanoma on southwest oncology group trials. *CANCER* 91:1148-1155 (2001).
- Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Liénard D, Guillaume P, Romero P, Cerottini JC, Rimoldi D: Frequent cytolytic T-cell responses to peptide IMAGE-A10(254-262) in melanoma. *CANCER RES* 61:509-512 (2001).
- vandenOord JJ, Delabie J: Binding of rabbit immunoglobulins to melanoma cells: a pitfall in the immunohistochemical study of malignant melanoma. *VIRCHOWS ARCHIV* 438:421-422 (2001).
- Walsh P, Gibbs P, Gonzalez R: Sentinel lymph node mapping and biopsy in the evaluation of primary melanoma - Reply. *J AMER ACAD DERMATOL* 44:877 (2001).
- Wang DZ, Richmond A: Nuclear factor- κ B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. *J BIOL CHEM* 276:3650-3659 (2001).
- Wang E, Marincola FM: cDNA arrays and the enigma of melanoma immune responsiveness. *CANCER J* 7:16-23 (2001).
- Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X: Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. *GENE THERAPY* 8:542-550 (2001).
- Wang R, Dworak LJ, Lacy MJ: A panel immunoblot using co-incubated monoclonal antibodies for identification of melanoma cells. *J IMMUNOL METHOD* 249:167-183 (2001).
- Wang SQ, Setlow R, Berwick M, Polsky D, Marghoob AA, Kopf AW, Bart RS: Ultraviolet A and melanoma: A review. *J AMER ACAD DERMATOL* 44:837-846 (2001).
- Watabe E, Ito A, Asada H, Endo Y, Kobayashi T, Nakamoto K, Itami S, Takao S, Shinomura Y, Aikou T, Yoshikawa K, Matsuzawa Y, Kitamura Y, Nojima H: Structure, expression and chromosome mapping of MLZE, a novel gene which is preferentially expressed in metastatic melanoma cells. *JPN J CANCER RES* 92:140-151 (2001).
- Weber JS, Aparicio A: Novel immunologic approaches to the management of malignant melanoma. *CURR OPIN ONCOL* 13:124-128 (2001).
- Winograd E, Robles WM, Caldas ML, Cortes GT: Cytoadherence of the malaria-infected erythrocyte membrane to C32 melanoma cells after merozoites are released from parasitized infected cells. *PARASITOL RES* 87:264-268 (2001).
- Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Teates D, Neese P, Grosh WW, Petroni G, Engelhard VH, Slingluff GL: Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. *INT J CANCER* 92:703-711 (2001).
- Yang HC, Wang SW, Liu Z, Wu MWH, McAlpine B, Ansel J, Armstrong C, Wu GJ: Isolation and characterization of mouse MUC18 cDNA gene, and correlation of MUC18 expression in mouse melanoma cell lines with metastatic ability. *GENE* 265:133-145 (2001).

- Ye S, Dhillon S, Turner SJ, Bateman AC, Theaker JM, Pickering RM, Day I, Howell WM: Invasiveness of cutaneous malignant melanoma is influenced by Matrix Metalloproteinase 1 gene polymorphism. *CANCER RES* 61:1296-1298 (2001).
- Zhu ZY, Sanchez-Sweatman O, Huang XJ, Wiltout R, Khokha R, Zhao Q, Gorelik E: Anoikis and metastatic potential of Cloudman S91 melanoma cells. *CANCER RES* 61:1707-1716 (2001).
- Zilberstein J, Schreiber S, Bloemers MCWM, Bendel P, Neeman M, Schechtman E, Kohen F, Scherz A, Salomon Y: Antivascular treatment of solid melanoma tumors with bacteriochlorophyll-serine-based photodynamic therapy. *PHOTOCHEM PHOTOBIOLOG* 73:257-266 (2001).

MSH, POMC, GROWTH FACTORS & RECEPTORS

- ❖ Abdel-Malek ZA: Melanocortin receptors: their functions and regulation by physiological agonists and antagonists. *CELL MOL LIFE SCI* 58:434-441 (2001).
- ❖ Abdel-Malek ZA, Scott MC, Furumura N, Lamoreux ML, Ollmann M, Barsh GS, Hearing VJ: The melanocortin 1 receptor is the principal mediator of the effects of agouti signaling protein on mammalian melanocytes. *J CELL SCI* 114:1019-1024 (2001).
- Audinot V, Beauverger P, Lahaye C, Suply T, Rodriguez M, Ouvry C, Lamamy V, Imbert J, Rique H, Nahon JL, Galizzi JP, Canet E, Levens N, Fauchère JL, Boutin JA: Structure-activity relationship studies of melanin-concentrating hormone (MCH)-related peptide ligands at SLC-1, the human MCH receptor. *J BIOL CHEM* 276:13554-13562 (2001).
- Bar-Eli M: Gene regulation in melanoma progression by the AP-2 transcription factor. *PIGM CELL RES* 14:78-85 (2001).
- Bastiaens MT, terHuurne JAC, Kielich C, Gruis NA, Westendorp RGJ, Vermeer BJ, Bavinck NJB: Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. *AMER J HUM GENET* 68:884-894 (2001).
- Bird DJ, Potter IC, Sower SA, Baker BI: The distribution of melanin-concentrating hormone in the lamprey brain. *GEN COMP ENDOCRINOL* 121:232-241 (2001).
- Box NF, Duffy DL, Irving RE, Russell A, Chen W, Griffiths LR, Parsons PG, Green AC, Sturm RA: Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. *J INVEST DERMATOL* 116:224-229 (2001).
- Chan CK, Jans DA: Enhancement of MSH receptor- and GAL4-mediated gene transfer by switching the nuclear import pathway. *GENE THERAPY* 8:166-171 (2001).
- Chluba J, deSouza DL, Frisch B, Schuber F: Enhancement of gene delivery by an analogue of α -MSH in a receptor-independent fashion. *BBA BIOMEMBRANES* 1510:198-208 (2001).
- Contreras LM, deAlmeida RFM, Villalán J, Fedorov A, Prieto M: Interaction of α -melanocyte stimulating hormone with binary phospholipid membranes: Structural changes and relevance of phase behavior. *BIOPHYS J* 80:2273-2283 (2001).
- Cos S, Garcia-Bolado A, Sánchez-Barceló EJ: Direct antiproliferative effects of melatonin on two metastatic cell sublines of mouse melanoma (B16BL6 and PG19). *MELANOMA RES* 11:197-201 (2001).
- Dahlen DD, Lin NL, Liu YC, Broudy VC: Soluble Kit receptor blocks stem cell factor bioactivity in vitro. *LEUK RES* 25:413-421 (2001).
- Demidem A, Morvan D, Papon J, DeLatour M, Madelmont JC: Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. *CANCER RES* 61:2294-2300 (2001).
- Denef C, Roudbaraki M, VanBael A: Growth and differentiation factors derived from the N-terminal domain of pro-opiomelanocortin. *CLIN EXP PHARMACOL PHYSIOL* 28:239-243 (2001).
- Edward M: Melanoma cell-derived factors stimulate glycosaminoglycan synthesis by fibroblasts cultured as monolayers and within contracted collagen lattices. *BRIT J DERMATOL* 144:465-470 (2001).
- Frändberg PA, Doufexis M, Kapas S, Chhajlani V: Cysteine residues are involved in structure and function of melanocortin 1 receptor: Substitution of a cysteine residue in transmembrane segment two converts an agonist to antagonist. *BIOCHEM BIOPHYS RES COMMUN* 281:851-857 (2001).
- Gómez A, Wellbrock C, Gutbrod H, Dimitrijevic N, Schartl M: Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. *J BIOL CHEM* 276:3333-3340 (2001).
- Graff BA, Bjornæs I, Rofstad EK: Microvascular permeability of human melanoma xenografts to macromolecules: Relationships to tumor volumetric growth rate, tumor angiogenesis, and VEGF expression. *MICROVASCULAR RES* 61:187-198 (2001).
- Haskell-Luevano C, Monck EK: Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. *REGUL PEPTIDES* 99:1-7 (2001).
- Innominato PF, Libbrecht L, vandenOord JJ: Expression of neurotrophins and their receptors in pigment cell lesions of the skin. *J PATHOL* 194:95-100 (2001).
- Klusa V, Germane S, Svirskis S, Opmane B, Wikberg JES: The $\gamma(2)$ -MSH peptide mediates a central analgesic effect via a GABA-ergic mechanism that is independent from activation of melanocortin receptors. *NEUROPEPTIDES* 35:50-57 (2001).
- Marks DL, Ling N, Cone RD: Role of the central melanocortin system in cachexia. *CANCER RES* 61:1432-1438 (2001).
- Matteucci E, Castoldi R, Desiderio MA: Hepatocyte growth factor induces pro-apoptotic genes in HepG2 hepatoma but not in B16-F1 melanoma cells. *J CELL PHYSIOL* 186:387-396 (2001).
- Mountjoy KG, Kong PL, Taylor JA, Willard DH, Wilkison WO: Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells. *PHYSIOL GENOMICS* 5:11-19 (2001).
- Nirodi C, NagDas S, Gygi SP, Olson G, Aebersold R, Richmond A: A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. *J BIOL CHEM* 276:9366-9374 (2001).
- Özbek S, Peters M, Breuhahn K, Mann A, Blessing M, Fischer M, Schirmacher P, Mackiewicz A, Rose-John S: The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. *ONCOGENE* 20:972-979 (2001).
- Prusis P, Muceniece R, Mutule I, Mutulis F, Wikberg JES: Design of new small, cyclic melanocortin receptor-binding peptides using molecular modelling: Role of the His residue in the melanocortin peptide core. *EUR J MED CHEM* 36:137-146 (2001).

- Scholes AGM, Hagan S, Hiscott P, Damato BE, Grierson I: Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma. ARCH OPHTHALMOL 119:373-377 (2001).
- Teh MT, Sugden D: An endogenous 5-HT7 receptor mediates pigment granule dispersion in *Xenopus laevis* melanophores. BRIT J PHARMACOL 132:1799-1808 (2001).
- Teshigawara K, Takahashi S, Boswell T, Li Q, Tanaka S, Takeuchi S: Identification of avian α -melanocyte-stimulating hormone in the eye: temporal and spatial regulation of expression in the developing chicken. J ENDOCRINOL 168:527-537 (2001).
- Wardlaw SL: Obesity as a neuroendocrine disease: Lessons to be learned from proopiomelanocortin and melanocortin receptor mutations in mice and men. J CLIN ENDOCRINOL METAB 86:1442-1446 (2001).
- Yu YX, Heller A, Liehr T, Smith CC, Aurelian L: Expression analysis and chromosome location of a novel gene (H11) associated with the growth of human melanoma cells. INT J ONCOL 18:905-911 (2001).

DEVELOPMENTAL BIOLOGY

- Anderson MJ, Shelton GD, Cavenee WK, Arden KC: Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. PROC NATL ACAD SCI USA 98:1589-1594 (2001).
- Fuchs S, Amiel J, Claudel S, Lyonnet S, Corvol P, Pinet F: Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirschsprung's disease: Evidence for selective loss of G(i) coupling. MOL MED 7:115-124 (2001).
- Kadono S, Manaka I, Kawashima M, Kobayashi T, Imokawa G: The role of the epidermal endothelin cascade in the hyperpigmentation mechanism of lentigo senilis. J INVEST DERMATOL 116:571-577 (2001).
- Krähn G, Leiter U, Kaskel P, Udart M, Utikal J, Bezold G, Peter RU: Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. EUR J CANCER 37:251-259 (2001).
- Küstners B, Westphal JR, Smits D, Ruitter DJ, Wesseling P, Keilholz U, deWaal RMW: The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin $\alpha(v)\beta(3)$ expression. INT J CANCER 92:176-180 (2001).
- Li WJ, Judge H, Gragoudas ES, Seddon JM, Egan KM: Patterns of tumor initiation in choroidal melanoma. ARCH OPHTHALMOL 119:430 (2001).
- Maschhoff KL, Baldwin HS: Molecular determinants of neural crest migration. AMER J MED GENET 97:280-288 (2000).
- Pennisi D, Bowles J, Nagy A, Muscat G, Koopman P: Mice null for Sox18 are viable and display a mild coat defect. MOL CELL BIOL 20:9331-9336 (2000).
- Pingault V, Bondurand N, Lemort N, Sancandi M, Ceccherini I, Hugot JP, Jouk PS, Goossens M: A heterozygous endothelin 3 mutation in Waardenburg-Hirschsprung disease: is there a dosage effect of EDN3/EDNRB gene mutations on neurocristopathy phenotypes? J MED GENET 38:205-208 (2001).
- Roix JJ, Hagge-Greenberg A, Bissonnette DM, Rodick S, Russell LB, O'Brien TP: Molecular and functional mapping of the piebald deletion complex on mouse chromosome 14. GENETICS 157:803-815 (2001).
- Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R, Schäfer BW: PAX3 is expressed in human melanomas and contributes to tumor cell survival. CANCER RES 61:823-826 (2001).
- Wehrle-Haller B, Imhof BA: Stem cell factor presentation to c-kit - Identification of a basolateral targeting domain. J BIOL CHEM 276:12667-12674 (2001).
- Xue L, Li XL, Noll M: Multiple protein functions of Paired in Drosophila development and their conservation in the Gooseberry and Pax3 homologs. DEVELOPMENT 128:395-405 (2001).

DIFFERENTIATION

- ❖ Brilliant MH: The mouse *p pink-eyed dilution* and human P genes, oculocutaneous albinism type 2 (OCA2), and melanosomal pH. PIGM CELL RES 14:86-93 (2001).
- Camp E, Lardelli M: Tyrosinase gene expression in zebrafish embryos. DEV GENES EVOL 211:150-153 (2001).
- Deacon SW, Gelfand VI: Of yeast, mice, and men: Rab proteins and organelle transport. J CELL BIOL 152:F21-F23 (2001).
- ❖ Fang D, Kute T, Setaluri V: Regulation of tyrosinase-related protein-2 (TYRP2) in human melanocytes: Relationship to growth and morphology. PIGM CELL RES 14:132-139 (2001).
- ❖ Halaban R, Cheng E, Svedine S, Aron R, Hebert DN: Proper folding and endoplasmic reticulum to Golgi transport of tyrosinase are induced by its substrates, DOPA and tyrosine. J BIOL CHEM 276:11933-11938 (2001).
- Hofele K, Sedelis M, Auburger GW, Morgan S, Huston JP, Schwarting RKW: Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility. EXP NEUROL 168:116-122 (2001).
- Hsieh YY, Wu JY, Chang CC, Tsai FJ, Lee CC, Tsai HD, Tsai CH: Prenatal diagnosis of oculocutaneous albinism two mutations located at the same allele. PRENATAL DIAG 21:200-201 (2001).
- Jungbluth AA, King R, Fisher DE, Iversen K, Coplan K, Kolb D, Williamson B, Chen YT, Stockert E, Old LJ, Busam KJ: Immunohistochemical and reverse transcription-polymerase chain reaction expression analysis of tyrosinase and microphthalmia-associated transcription factor in angiomyolipomas. APPL IMMUNOHISTOCHEM MOL MORP 9:29-34 (2001).
- ❖ Lamoreux ML, Wakamatsu K, Ito S: Interaction of major coat color gene functions in mice as studied by chemical analysis of eumelanin and pheomelanin. PIGM CELL RES 14:23-31 (2001).
- Laveda F, Núñez-Delicado E, García-Carmona F, Sánchez-Ferrer A: Proteolytic activation of latent Paraguaya peach PPO. Characterization of monophenolase activity. J AGR FOOD CHEM 49:1003-1008 (2001).
- Lee Y, Broxmeyer HE: Synergistic activation of RSK correlates with c-fos induction in MO7e cells stimulated with GM-CSF plus steel factor. BIOCHEM BIOPHYS RES COMMUN 281:897-901 (2001).

- Loeffler KU, Sahm M, Spitznas M: Short-time application of latanoprost does not stimulate melanogenesis in bovine ocular melanin-containing cells in vitro. *OPHTHALMIC RES* 33:102-106 (2001).
- ❖ Manga P, Kromberg JGR, Turner A, Jenkins T, Ramsay M: In southern Africa, brown oculocutaneous albinism (BOCA) maps to the OCA2 locus on chromosome 15q: P-gene mutations identified. *AMER J HUM GENET* 68:782-787 (2001).
 - Mendiratta SK, Thai G, Eslahi NK, Thull NM, Matar M, Bronte V, Pericle F: Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. *CANCER RES* 61:859-863 (2001).
 - ❖ Mishima Y: New era of cell re-discovery led to the control of melanogenesis/melanoma: A scientific journey into Terra incognita. *PIGM CELL RES* 14:47-70 (2001).
 - Nakamura Y, Torikai K, Ohigashi H: A catechol antioxidant protocatechuic acid potentiates inflammatory leukocyte-derived oxidative stress in mouse skin via a tyrosinase bioactivation pathway. *FREE RADICAL BIOL MED* 30:967-978 (2001).
 - ❖ Nappi AJ, Vass E: The effects of nitric oxide on the oxidations of L-dopa and dopamine mediated by tyrosinase and peroxidase. *J BIOL CHEM* 276:11214-11222 (2001).
 - Olivares C, Jiménez-Cervantes C, Lozano JA, Solano F, García-Borrón JC: The 5,6-dihydroxyindole-2-carboxylic acid (DHICA) oxidase activity of human tyrosinase. *BIOCHEM J* 354:131-139 (2001).
 - Paine C, Sharlow E, Liebel F, Eisinger M, Shapiro S, Seiberg M: An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. *J INVEST DERMATOL* 116:587-595 (2001).
 - Pérez-Gilabert M, Morte A, Honrubia M, García-Carmona F: Partial purification, characterization, and histochemical localization of fully latent desert truffle (*Terfezia claveryi Chatin*) polyphenol oxidase. *J AGR FOOD CHEM* 49:1922-1927 (2001).
 - Purrello M, Scalia M, Corsaro C, DiPietro C, Piro S, Sichel G: Melanosynthesis, differentiation, and apoptosis in Kupffer cells from *Rana esculenta*. *PIGM CELL RES* 14:126-131 (2001).
 - ❖ Rieber MS, Welch DR, Rieber M: Suppression of C8161 melanoma metastatic ability by chromosome 6 induces differentiation-associated tyrosinase and decreases proliferation on adhesion-restrictive substrates mediated by overexpression of p21WAF1 and down-regulation of bcl-2 and cyclin D3. *BIOCHEM BIOPHYS RES COMMUN* 281:159-165 (2001).
 - Rikke BA, Simpson VJ, Montoliu L, Johnson TE: No effect of albinism on sedative-hypnotic sensitivity to ethanol and anesthetics. *ALCOHOL CLIN EXP RES* 25:171-176 (2001).
 - ❖ Samaraweera P, Shen B, Newton JM, Barsh GS, Orlow SJ: The mouse ocular albinism 1 gene product is an endolysosomal protein. *EXP EYE RES* 72:319-329 (2001).
 - Soler-Rivas C, Möller AC, Arpin N, Olivier JM, Wichers HJ: Induction of a tyrosinase mRNA in *Agaricus bisporus* upon treatment with a tolaasin preparation from *Pseudomonas tolaasii*. *PHYSIOL MOLEC PLANT PATHOL* 58:95-99 (2001).
 - Stoitchkov K, Letellier S, Garnier JP, Toneva M, Naumova E, Peytcheva E, Tzankov N, Bousquet B, Morel P, LeBricon T: Evaluation of standard tyrosinase RT-PCR in melanoma patients by the use of the LightCycler(TM) system. *CLIN CHIM ACTA* 306:133-138 (2001).
 - Tsao H, Nadiminti U, Sober AJ, Bigby M: A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. *ARCH DERMATOL* 137:325-330 (2001).
 - Udono T, Takahashi K, Yasumoto K, Yoshizawa M, Takeda K, Abe T, Tamai M, Shibahara S: Expression of tyrosinase-related protein 2/DOPochrome tautomerase in the retinoblastoma. *EXP EYE RES* 72:225-234 (2001).
 - ❖ Ujvári A, Aron R, Eisenhaure T, Cheng E, Parag HA, Smicun Y, Halaban R, Hebert DN: Translation rate of human tyrosinase determines its N-linked glycosylation level. *J BIOL CHEM* 276:5924-5931 (2001).